Dominic P Amara, MD
Obstetrics/Gynecology · Sonoma
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Offices
- 4
- Since medical school
- 35 years
- University of California, San Francisco School of Medicine, 1991
Offices
4 locations · Sonoma Valley Community Health Center · Obhg California PC
Looking this up.
Hospitals listed: Providence Queen of the Valley Medical Center · Sonoma Valley Hospital. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Amara’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Providence Queen of the Valley Medical CenterNapa, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.107, Oct 2024 – Sep 2025
- Sonoma Valley HospitalSonoma, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency departmentPatients rate it 4 of 5 · 79% would definitely recommend itOverall rating: 2 of 5 starsNo measure marked better or worse than the national rate
See every measure and the patient survey for Providence Queen of the Valley Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 2 better, 9 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.107 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.9 (0 to 1.92) · 609 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.85 (0.5 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 191.43 (130.54 to 252.33) · 39 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 46 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.1 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 135 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12 · 271 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.7 · 376 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11 · 175 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 1,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.21 (0 to 0.41) · 4,152 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.43) · 4,188 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.81 (1.63 to 5.99) · 803 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.21) · 250 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.19 (0.62 to 3.77) · 742 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.45 (0.91 to 16) · 250 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.58 (1.75 to 9.42) · 250 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.65 (0.17 to 3.13) · 152 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.19 (0 to 0.94) · 2,994 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.684 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.887 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 133 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 270 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -4.8 · 143 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -22.1 · 316 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -1 · 399 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 20.4 · 337 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.3 (3.5 to 7.8) · 107 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (9.8 to 17.7) · 107 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 76 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.4 to 16.2) · 848 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.4) · 423 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 40% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
See every measure and the patient survey for Sonoma Valley Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 6 the same, 0 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.11 (0.63 to 1.6) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 37 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.6 · 106 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 35 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 5.6 · 345 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.21 (0 to 0.44) · 713 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.05 to 0.48) · 660 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.36 (0.77 to 5.94) · 101 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.65 (0 to 3.38) · 27 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.31 (0.58 to 4.03) · 100 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.86 (0 to 18.76) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (0.84 to 9.45) · 27 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.12 (0 to 2.33) · 540 cases | No different | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.651 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.1 · 60 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 15.5 · 47 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18 · 105 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 47 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.6 (10.2 to 17.9) · 486 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.6 to 1.3) · 83 cases | No different | Jan 2024 – Dec 2024 |
What patients said (164 patients answered, 31% of those asked)
| Cleanliness | 4 |
| Nurse communication | 5 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 85% |
| Doctors "always" communicated well | 88% |
| Staff "always" explained | 65% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 84% |
| Doctors "always" listened carefully | 88% |
| Doctors "always" treated them with courtesy and respect | 92% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 81% |
| Nurses "always" listened carefully | 82% |
| Nurses "always" treated them with courtesy and respect | 91% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 53% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$33,190
Medicare paid this office $33,190 for 175 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 130 | $12,120 | $88 |
| Short return visit (20+ min) | 72 | $9,070 | $70 |
| New patient visit (45+ min) | 34 | $3,715 | $109 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 17 | $1,955 | $109 |
| Manual urinalysis test with examination using microscope, non-automated | 11 | $63 | $4 |
Who their Medicare patients are
175 Original Medicare patients in 2024. Average age 75 · Women 100% · Also on Medicaid 6% · Health risk score 0.89. Above the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 61% · Depression 23% · Cancer 21% · Chronic kidney disease 17% · Diabetes 15% · Coronary heart disease 12% · Atrial fibrillation 11% · Heart failure 8% · COPD 7%.
The office billed $88,508, Medicare allowed $48,693 and paid $33,190; for 373 services of 31 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 175 | 373 | 75 | 0.89 | $88,508 | $33,190 |
| 2023 | 191 | 394 | 75 | 0.91 | $85,764 | $34,421 |
| 2022 | 200 | 429 | 75 | 0.82 | $112,894 | $44,176 |
| 2021 | 219 | 504 | 74 | 0.77 | $103,889 | $41,273 |
| 2020 | 213 | 485 | 73 | 0.75 | $96,065 | $34,131 |
| 2019 | 270 | 650 | 74 | 0.83 | $147,606 | $53,732 |
| 2018 | 268 | 619 | 74 | 0.76 | $126,613 | $41,529 |
| 2017 | 300 | 704 | 73 | 0.79 | $156,201 | $51,519 |
| 2016 | 324 | 734 | 73 | 0.77 | $156,687 | $53,554 |
| 2015 | 343 | 761 | 72 | 0.78 | $143,964 | $48,703 |
| 2014 | 341 | 713 | 72 | 0.77 | $127,471 | $45,529 |
| 2013 | 326 | 742 | 71 | 0.77 | $139,710 | $46,390 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Return visit (30+ min) | 124 | $11,879 | $94 |
| Short return visit (20+ min) | 84 | $10,799 | $68 |
| New patient visit (45+ min) | 35 | $4,129 | $118 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 17 | $2,099 | $105 |
| Manual urinalysis test with examination using microscope, non-automated | 14 | $91 | $4 |
2022: 6 services
| Short return visit (20+ min) | 100 | $11,798 | $68 |
| Return visit (30+ min) | 106 | $10,786 | $95 |
| New patient visit (45+ min) | 39 | $4,927 | $126 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 23 | $2,887 | $111 |
| Stool analysis for blood to screen for colon tumors | 20 | $87 | $4 |
| Manual urinalysis test with examination using microscope, non-automated | 12 | $72 | $4 |
2021: 6 services
| Return visit (30+ min) | 126 | $12,990 | $96 |
| Short return visit (20+ min) | 108 | $11,858 | $65 |
| New patient visit (45+ min) | 32 | $3,880 | $121 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 23 | $2,704 | $113 |
| Stool analysis for blood to screen for colon tumors | 62 | $272 | $4 |
| Manual urinalysis test with examination using microscope, non-automated | 19 | $105 | $4 |
2020: 6 services
| Return visit (30+ min) | 121 | $10,686 | $82 |
| Short return visit (20+ min) | 103 | $8,674 | $51 |
| New patient visit (45+ min) | 24 | $2,865 | $119 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 18 | $2,097 | $105 |
| Stool analysis for blood to screen for colon tumors | 72 | $314 | $4 |
| Manual urinalysis test with examination using microscope, non-automated | 17 | $120 | $4 |
2019: 6 services
| Short return visit (20+ min) | 160 | $13,348 | $53 |
| Return visit (30+ min) | 132 | $10,297 | $74 |
| New patient visit (45+ min) | 47 | $5,850 | $124 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 24 | $2,520 | $105 |
| Stool analysis for blood to screen for colon tumors | 95 | $408 | $4 |
| Manual urinalysis test with examination using microscope, non-automated | 19 | $114 | $4 |
2018: 6 services
| Return visit (30+ min) | 185 | $13,389 | $69 |
| Short return visit (20+ min) | 109 | $10,587 | $51 |
| New patient visit (45+ min) | 23 | $2,814 | $122 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 18 | $1,968 | $98 |
| Stool analysis for blood to screen for colon tumors | 94 | $403 | $4 |
| Manual urinalysis test with examination using microscope, non-automated | 23 | $138 | $4 |
2017: 6 services
| Return visit (30+ min) | 214 | $15,636 | $72 |
| Short return visit (20+ min) | 110 | $12,956 | $53 |
| New patient visit (45+ min) | 40 | $4,933 | $123 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 17 | $1,811 | $101 |
| Stool analysis for blood to screen for colon tumors | 80 | $350 | $4 |
| Manual urinalysis test with examination using microscope, non-automated | 24 | $145 | $4 |
2016: 8 services
| Return visit (30+ min) | 238 | $18,665 | $76 |
| Short return visit (20+ min) | 108 | $11,767 | $55 |
| New patient visit (45+ min) | 46 | $5,802 | $126 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 32 | $3,519 | $104 |
| New patient visit (60+ min) | 12 | $1,882 | $157 |
| Biopsy of lining of uterus | 15 | $1,329 | $89 |
| Stool analysis for blood to screen for colon tumors | 102 | $443 | $4 |
| Manual urinalysis test with examination using microscope, non-automated | 17 | $102 | $4 |
2015: 7 services
| Return visit (30+ min) | 246 | $18,693 | $74 |
| Short return visit (20+ min) | 110 | $11,741 | $51 |
| New patient visit (45+ min) | 47 | $5,355 | $114 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 22 | $2,559 | $102 |
| New patient visit (60+ min) | 12 | $1,855 | $155 |
| Stool analysis for blood to screen for colon tumors | 106 | $460 | $4 |
| Manual urinalysis test with examination using microscope, non-automated | 25 | $122 | $4 |
2014: 7 services
| Return visit (30+ min) | 241 | $18,301 | $74 |
| Short return visit (20+ min) | 120 | $11,060 | $53 |
| New patient visit (45+ min) | 42 | $5,499 | $131 |
| New patient visit (60+ min) | 17 | $2,517 | $148 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 14 | $1,578 | $105 |
| Stool analysis for blood to screen for colon tumors | 118 | $513 | $4 |
| Manual urinalysis test with examination using microscope, non-automated | 14 | $68 | $4 |
2013: 7 services
| Return visit (30+ min) | 229 | $18,606 | $78 |
| Short return visit (20+ min) | 121 | $13,234 | $54 |
| New patient visit (45+ min) | 24 | $2,801 | $117 |
| New patient visit (60+ min) | 15 | $2,080 | $139 |
| Short return visit (20+ min) | 12 | $559 | $40 |
| Stool analysis for blood to screen for colon tumors | 103 | $455 | $4 |
| Manual urinalysis test with examination using microscope, non-automated | 16 | $99 | $4 |
Medicaid work
$331,029 in 2024
Medicaid paid $331,029 for 3,039 billed services this clinician did in 2024, up to 57 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 953 | $288,959 |
| Prenatal care, at-risk enhanced service; antepartum management | 461 | $36,794 |
| Short return visit (20+ min) | 419 | $4,873 |
| Long return visit (40+ min) | 98 | $223 |
| URINE PREGNANCY TEST | 62 | $132 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 506 | $44 |
| HEMOGLOBIN | 62 | $3 |
| Service | 478 | $0 |
| 2024 | 3,039 | 8 | 57 | $331,029 |
| 2023 | 2,549 | 10 | 56 | $286,829 |
| 2022 | 2,337 | 8 | 52 | $234,658 |
| 2021 | 4,029 | 13 | 64 | $379,424 |
| 2020 | 2,743 | 13 | 62 | $274,640 |
| 2019 | 1,344 | 5 | 54 | $244,492 |
| 2018 | 1,908 | 4 | 66 | $342,982 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 949 | $244,489 |
| Prenatal care, at-risk enhanced service; antepartum management | 386 | $30,819 |
| Short return visit (20+ min) | 353 | $8,441 |
| Annual depression screening, 5 to 15 minutes | 108 | $1,387 |
| Annual alcohol misuse screening, 5 to 15 minutes | 83 | $1,051 |
| Screening for depression is documented as negative, a follow-up plan is not required | 53 | $417 |
| Short return visit | 17 | $141 |
| URINE PREGNANCY TEST | 24 | $54 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 272 | $30 |
| Service | 304 | $0 |
2022
| Clinic visit/encounter, all-inclusive | 855 | $203,448 |
| Prenatal care, at-risk enhanced service; antepartum management | 318 | $25,001 |
| Short return visit (20+ min) | 103 | $2,813 |
| Annual depression screening, 5 to 15 minutes | 200 | $1,891 |
| Annual alcohol misuse screening, 5 to 15 minutes | 116 | $1,094 |
| Screening for depression is documented as negative, a follow-up plan is not required | 46 | $362 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 347 | $49 |
| Service | 352 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 1,455 | $344,812 |
| Prenatal care, at-risk enhanced service; antepartum management | 324 | $25,201 |
| Annual depression screening, 5 to 15 minutes | 576 | $4,286 |
| Short return visit (20+ min) | 149 | $2,341 |
| Annual alcohol misuse screening, 5 to 15 minutes | 282 | $2,198 |
| Prenatal care, at-risk enhanced service; education | 12 | $303 |
| Health behavior assessment | 14 | $236 |
| Brief emotional/behavioral assessment (eg, depression inventory, attention-deficit/hyperactivity disorder [ADHD] scale), with scoring and documentation, per standardized instrument | 16 | $25 |
| URINE PREGNANCY TEST | 19 | $23 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 542 | $0 |
| Service | 516 | $0 |
| Service | 12 | $0 |
2020
| Clinic visit/encounter, all-inclusive | 1,076 | $248,218 |
| Prenatal care, at-risk enhanced service; antepartum management | 284 | $17,267 |
| Short return visit (20+ min) | 137 | $3,790 |
| ANTEPARTUM CARE ONLY 4-6 VISITS | 62 | $3,750 |
| Annual alcohol misuse screening, 5 to 15 minutes | 88 | $665 |
| Health behavior assessment | 30 | $530 |
| Preventive medicine counseling and risk factor reduction intervention for individual, approximately 15 minutes | 17 | $311 |
| URINE PREGNANCY TEST | 42 | $60 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 416 | $29 |
| Annual depression screening, 5 to 15 minutes | 164 | $21 |
| HEMOGLOBIN | 13 | $0 |
| Service | 387 | $0 |
2019
| Clinic visit/encounter, all-inclusive | 1,087 | $236,527 |
| ANTEPARTUM CARE ONLY 4-6 VISITS | 117 | $7,076 |
| Preventive medicine counseling and risk factor reduction intervention for individual, approximately 15 minutes | 41 | $883 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 44 | $6 |
| Service | 55 | $0 |
2018
| Clinic visit/encounter, all-inclusive | 1,584 | $328,246 |
| ANTEPARTUM CARE ONLY 4-6 VISITS | 194 | $11,733 |
| Preventive medicine counseling and risk factor reduction intervention for individual, approximately 15 minutes | 82 | $1,833 |
| Prenatal care, at-risk enhanced service; education | 48 | $1,169 |
Drugs they prescribed that Part D paid
$52,429
Pharmacies billed $52,429 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
480 generic and 60 brand-name prescriptions · $52,429 in drug cost · 26 antibiotic prescriptions to 12 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Estradiol | 212 | $13,213 | $62 |
| Estring | 19 | $10,089 | $531 |
| Premarin | 12 | $5,545 | $462 |
| Valacyclovir | 52 | $2,560 | $49 |
| Progesterone | 35 | $1,285 | $37 |
See all 10 drugs
| Estradiol | 212 | $13,213 | $62 |
| Estring | 19 | $10,089 | $531 |
| Premarin | 12 | $5,545 | $462 |
| Valacyclovir | 52 | $2,560 | $49 |
| Progesterone | 35 | $1,285 | $37 |
| Estradiol (Once Weekly) | 12 | $1,254 | $105 |
| Clobetasol Propionate | 17 | $609 | $36 |
| Oxybutynin Chloride | 33 | $496 | $15 |
| Oxybutynin Chloride Er | 12 | $209 | $17 |
| Nystatin-Triamcinolone | 14 | $193 | $14 |
Year by year
| 2024 | 540 | 168 | None | 11% | $52,429 |
| 2023 | 532 | 153 | None | None | $69,021 |
| 2022 | 535 | 154 | None | 19% | $62,947 |
| 2021 | 592 | 162 | None | 22% | $73,839 |
| 2020 | 546 | 151 | None | 23% | $84,592 |
| 2019 | 563 | 160 | 2% (12) | 28% | $91,324 |
| 2018 | 504 | 146 | None | 29% | $81,032 |
| 2017 | 528 | 150 | None | 34% | $79,721 |
| 2016 | 430 | 131 | None | 39% | $58,973 |
| 2015 | 470 | 142 | None | None | $55,724 |
| 2014 | 484 | 136 | None | None | $44,842 |
| 2013 | 534 | 146 | None | None | $51,258 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 11 drugs
| Estradiol | 169 | $14,509 | $86 |
| Estring | 23 | $12,604 | $548 |
| Premarin | 18 | $9,037 | $502 |
| Myrbetriq | 11 | $8,047 | $732 |
| Climara Pro | 21 | $6,728 | $320 |
| Valacyclovir | 73 | $2,918 | $40 |
| Estradiol (Once Weekly) | 17 | $1,045 | $61 |
| Clobetasol Propionate | 18 | $611 | $34 |
| Oxybutynin Chloride | 19 | $418 | $22 |
| Raloxifene | 11 | $396 | $36 |
| Nitrofurantoin Mono-Macro | 11 | $250 | $23 |
2022: 11 drugs
| Estradiol | 185 | $16,558 | $90 |
| Estring | 23 | $11,896 | $517 |
| Premarin | 18 | $7,109 | $395 |
| Climara Pro | 15 | $6,312 | $421 |
| Valacyclovir | 56 | $1,992 | $36 |
| Estradiol (Once Weekly) | 24 | $1,776 | $74 |
| Clobetasol Propionate | 18 | $1,072 | $60 |
| Raloxifene | 13 | $909 | $70 |
| Nitrofurantoin Mono-Macro | 13 | $332 | $26 |
| Cephalexin | 11 | $48 | $4 |
| Triamcinolone Acetonide | 11 | $37 | $3 |
2021: 9 drugs
| Estradiol | 212 | $19,684 | $93 |
| Premarin | 29 | $10,319 | $356 |
| Estring | 19 | $9,529 | $502 |
| Climara Pro | 17 | $5,933 | $349 |
| Valacyclovir | 63 | $2,148 | $34 |
| Raloxifene | 17 | $1,321 | $78 |
| Clobetasol Propionate | 24 | $910 | $38 |
| Oxybutynin Chloride | 33 | $649 | $20 |
| Nitrofurantoin Mono-Macro | 17 | $380 | $22 |
2020: 12 drugs
| Estradiol | 185 | $27,394 | $148 |
| Premarin | 32 | $10,490 | $328 |
| Myrbetriq | 12 | $9,085 | $757 |
| Prempro | 13 | $7,165 | $551 |
| Estring | 15 | $7,043 | $470 |
| Climara Pro | 18 | $5,860 | $326 |
| Valacyclovir | 68 | $2,266 | $33 |
| Raloxifene | 19 | $2,125 | $112 |
| Oxybutynin Chloride | 25 | $955 | $38 |
| Nitrofurantoin Mono-Macro | 15 | $387 | $26 |
| Clobetasol Propionate | 15 | $292 | $19 |
| Acyclovir | 11 | $292 | $27 |
2019: 13 drugs
| Estradiol | 148 | $24,778 | $167 |
| Premarin | 46 | $13,302 | $289 |
| Myrbetriq | 12 | $10,091 | $841 |
| Estring | 20 | $8,904 | $445 |
| Prempro | 18 | $8,884 | $494 |
| Climara Pro | 17 | $5,226 | $307 |
| Yuvafem | 14 | $3,741 | $267 |
| Valacyclovir | 77 | $1,893 | $25 |
| Raloxifene | 16 | $1,463 | $91 |
| Clobetasol Propionate | 18 | $1,188 | $66 |
| Oxybutynin Chloride | 19 | $594 | $31 |
| Nitrofurantoin Mono-Macro | 17 | $426 | $25 |
| Oxybutynin Chloride Er | 12 | $229 | $19 |
2018: 13 drugs
| Estradiol | 124 | $17,338 | $140 |
| Premarin | 42 | $12,029 | $286 |
| Estring | 24 | $10,114 | $421 |
| Yuvafem | 25 | $9,351 | $374 |
| Estrace | 21 | $6,487 | $309 |
| Prempro | 15 | $6,110 | $407 |
| Climara Pro | 14 | $4,634 | $331 |
| Raloxifene | 16 | $1,428 | $89 |
| Valacyclovir | 65 | $1,244 | $19 |
| Clobetasol Propionate | 14 | $934 | $67 |
| Nitrofurantoin Mono-Macro | 14 | $383 | $27 |
| Oxybutynin Chloride | 11 | $186 | $17 |
| Acyclovir | 13 | $132 | $10 |
2017: 14 drugs
| Estrace | 50 | $14,118 | $282 |
| Premarin | 52 | $13,378 | $257 |
| Estring | 31 | $11,726 | $378 |
| Yuvafem | 32 | $8,933 | $279 |
| Prempro | 33 | $8,106 | $246 |
| Estradiol | 86 | $6,057 | $70 |
| Myrbetriq | 11 | $3,587 | $326 |
| Clobetasol Propionate | 17 | $1,234 | $73 |
| Raloxifene | 16 | $916 | $57 |
| Valacyclovir | 43 | $858 | $20 |
| Oxybutynin Chloride | 15 | $834 | $56 |
| Progesterone | 12 | $697 | $58 |
| Nitrofurantoin Mono-Macro | 14 | $352 | $25 |
| Fluoxetine | 13 | $33 | $3 |
2016: 13 drugs
| Estring | 41 | $12,806 | $312 |
| Estrace | 45 | $11,895 | $264 |
| Premarin | 33 | $8,010 | $243 |
| Prempro | 25 | $4,924 | $197 |
| Vagifem | 12 | $4,037 | $336 |
| Estradiol | 90 | $3,834 | $43 |
| Vesicare | 12 | $3,502 | $292 |
| Raloxifene | 15 | $1,607 | $107 |
| Clobetasol Propionate | 11 | $1,483 | $135 |
| Progesterone | 12 | $556 | $46 |
| Valacyclovir | 27 | $417 | $15 |
| Nitrofurantoin Mono-Macro | 11 | $275 | $25 |
| Fluoxetine | 13 | $33 | $3 |
2015: 14 drugs
| Estrace | 54 | $12,344 | $229 |
| Estring | 37 | $9,717 | $263 |
| Premarin | 31 | $6,209 | $200 |
| Vesicare | 16 | $3,963 | $248 |
| Prempro | 24 | $3,954 | $165 |
| Estradiol | 86 | $3,060 | $36 |
| Vagifem | 15 | $2,977 | $198 |
| Evista | 13 | $2,605 | $200 |
| Clobetasol Propionate | 16 | $1,723 | $108 |
| Divigel | 13 | $1,255 | $97 |
| Valacyclovir | 32 | $848 | $26 |
| Progesterone | 15 | $674 | $45 |
| Nitrofurantoin | 11 | $296 | $27 |
| Fluoxetine | 12 | $82 | $7 |
2014: 13 drugs
| Estrace | 48 | $7,876 | $164 |
| Vagifem | 27 | $6,308 | $234 |
| Premarin | 30 | $5,100 | $170 |
| Prempro | 34 | $4,567 | $134 |
| Evista | 12 | $2,833 | $236 |
| Estring | 11 | $2,434 | $221 |
| Estradiol | 94 | $2,265 | $24 |
| Clobetasol Propionate | 22 | $1,677 | $76 |
| Vivelle-Dot | 15 | $1,672 | $111 |
| Progesterone | 24 | $1,181 | $49 |
| Valacyclovir | 29 | $1,008 | $35 |
| Nitrofurantoin Mono-Macro | 19 | $623 | $33 |
| Fluoxetine | 12 | $60 | $5 |
2013: 17 drugs
| Estrace | 48 | $7,120 | $148 |
| Premarin | 30 | $5,619 | $187 |
| Vagifem | 33 | $5,482 | $166 |
| Evista | 16 | $4,257 | $266 |
| Prempro | 33 | $3,714 | $113 |
| Vesicare | 18 | $3,703 | $206 |
| Vivelle-Dot | 30 | $3,615 | $121 |
| Estring | 18 | $3,581 | $199 |
| Toviaz | 13 | $2,156 | $166 |
| Progesterone | 21 | $1,973 | $94 |
| Estradiol | 76 | $1,664 | $22 |
| Valacyclovir | 25 | $1,187 | $47 |
| Clobetasol Propionate | 14 | $1,163 | $83 |
| Nystatin-Triamcinolone | 13 | $736 | $57 |
| Nitrofurantoin Mono-Macro | 14 | $579 | $41 |
| Norgestimate-Ethinyl Estradiol | 12 | $189 | $16 |
| Fluoxetine | 17 | $114 | $7 |
Money from drug and device companies
$177 in 2025
| 2025 | 4 | 5 | None | $177 |
| 2024 | 4 | 9 | None | $292 |
| 2023 | 3 | 10 | None | $318 |
| 2022 | 4 | 8 | None | $257 |
| 2021 | 4 | 6 | None | $138 |
| 2020 | 2 | 3 | None | $66 |
| 2019 | 3 | 6 | None | $206 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Medtronic | Signia | $73 | 1 payment
|
| Organon | Nexplanon | $51 | 2 payments
|
| Hologic Sales and Service | Novasure | $28 | 1 payment
|
| Biogen | Zurzuvae | $25 | 1 payment
|
See all 5 published payments
| Organon | Meals · 2025-11-26 | Nexplanon | $28 |
| Medtronic | Meals · 2025-06-05 | Signia | $73 |
| Biogen | Meals · 2025-04-16 | Zurzuvae | $25 |
| Organon | Meals · 2025-04-09 | Nexplanon | $23 |
| Hologic Sales and Service | Meals · 2025-01-08 | Novasure | $28 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $292
| Astellas Pharma US | Veozah | $215 | 6 payments
|
| Hologic Sales and Service | Myosure Tissue Removal Device | $38 | 1 payment
|
| Organon | Nexplanon | $32 | 1 payment
|
| Mayne Pharma Commercial | None | $7 | 1 payment
|
2023: $318
| Astellas Pharma US | Veozah | $192 | 5 payments
|
| Pfizer | Myfembree | $75 | 3 payments
|
| Organon | Nexplanon | $51 | 2 payments
|
2022: $257
| Astellas Pharma US | Myrbetriq | $131 | 3 payments
|
| Organon | Nexplanon | $79 | 3 payments
|
| Pfizer | Myfembree | $30 | 1 payment
|
| Mayne Pharma | None | $17 | 1 payment
|
2021: $138
| Organon | Nexplanon | $47 | 2 payments
|
| Myovant Sciences | Myfembree | $43 | 2 payments
|
| Biohaven Pharmaceuticals | Nurtec Odt | $26 | 1 payment
|
| TherapeuticsMD | Annovera | $22 | 1 payment
|
2020: $66
| TherapeuticsMD | Annovera | $43 | 2 payments
|
| AbbVie | Lo Loestrin Fe | $23 | 1 payment
|
2019: $206
| AbbVie | Orilissa | $118 | 1 payment
|
| AMAG Pharmaceuticals | Intrarosa | $72 | 4 payments
|
| TherapeuticsMD | Imvexxy | $16 | 1 payment
|
Professional record
- NPI
- 1518958313
- Licence
- CA OOG762260
- Trained
- University of California, San Francisco School of Medicine, 1991 · 35 years ago
- Group
- Sonoma Valley Community Health Center · Obhg California PC
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G76220
- Taxonomy
- Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 181 Andrieux St, Suite 108, Sonoma, CA, 95476
- NPI first listed
- 2005-10-31
- NPI last updated
- 2013-08-01
This is when the NPI record was last certified, not a medical board exam.